Patent ID: 11939390
Assignee: SANOFI-AVENTIS U.S. LLC
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 7:
8. The method according to claim 7, wherein the anti-CD38 antibody, the pomalidomide, and the dexamethasone are further administered in one or more 28-day cycles following the first 28-day cycle,
wherein the anti-CD38 antibody is administered on Days 1 and 15 of the one or more 28-day cycles following the first 28-day cycle, the pomalidomide is administered on each of Days 1-21 of the one or more 28-day cycles following the first 28-day cycle, and the dexamethasone is administered on Days 1, 8, 15, and 22 of the one or more 28-day cycles following the first 28-day cycle.